NASDAQ:IMUX
Immunic Inc. Stock News
$1.29
+0.0450 (+3.61%)
At Close: May 20, 2024
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i
The Global Automotive Inertial Measurement Unit Sensors Market will grow by USD 6.77 bn during 2020-2024
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, an
Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
12:29am, Wednesday, 05'th Aug 2020
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, to
Immunic Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:IMUX)
10:33am, Tuesday, 04'th Aug 2020
Immunic announced positive top line data for IMU-838. Catalyst Pharma gets stung in FDA lawsuit.
Latest Generation YellowScan Mapping Systems Rely on Velodyne Lidar Sensors to Meet Demanding Needs of Survey Professionals
12:00am, Tuesday, 04'th Aug 2020
Velodyne Lidar announced YellowScan systems use Velodyne’s lidar sensors to help achieve the high precision and accuracy needed in aerial 3D mapping.
Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
08:15pm, Monday, 03'rd Aug 2020
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, to
Immunic Spikes 35% In Pre-Market On Positive Multiple Sclerosis Data
09:04am, Monday, 03'rd Aug 2020
Immunic (IMUX) has announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company’s selective oral DHODH inhibitor, in patients with relapsing-remitting multipl
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today an
Deep Learning for Inertial Navigation
05:15pm, Saturday, 01'st Aug 2020
A short review of cutting edge deep learning-based solutions for inertial navigation.
The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
12:00am, Friday, 31'st Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 30)
Achieve Life Sciences Inc (NASDAQ: ACHV)
Annexon Inc (NASDAQ: ANNX) (IPOed July 24)
Atossa Therapeutics...
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
08:15pm, Thursday, 30'th Jul 2020
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today an
